Jonathan Gardner

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo's medicines.

The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in the U.S. or Europe.

The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.

Ziltivekimab's failure in a key trial hurt spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.

Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.